TB-500
TB-500 (Thymosin Beta-4 synthetic fragment)
Research Parameters
- Typical Dose Range
- 2 to 2.5 mg twice weekly (loading phase, 4 to 6 weeks). 2 mg weekly (maintenance).
- Half-Life
- ~2 to 3 hours (peptide); biological effects persist longer
- Administration Route
- Subcutaneous, Intramuscular
Dosing information is for research purposes only and has not been evaluated by the FDA.
Racehorses have been getting TB-500 for decades. That's not a slight. It's how the research protocol knowledge developed, because the animals getting it are seven-figure athletes whose owners demand it works. That translated into human research focused on the same problem: soft tissue injuries that heal slowly because the damage is deep, the blood supply is poor, or the athlete can't afford to stop training.
Where BPC-157 is the localized healer, TB-500 is the systemic one. Researchers study it for whole-body repair: injuries in one place benefit from it even if you inject somewhere else. That's the reason the two get stacked together more often than any other peptide pair. Different travel patterns, same end goal.
For research purposes only.
Mechanism of Action
TB-500 is a synthetic version of the active region of Thymosin Beta-4, a protein present in nearly every cell in the body. It upregulates actin, the protein that lets cells move and rebuild, which the research links to wound healing, reduced inflammation, and improved flexibility in damaged connective tissue.
Citations
Frequently Asked Questions
- What is TB-500 used for in research?
Research centers on systemic tissue repair, wound healing, and inflammation reduction. It's most often studied in contexts involving tendon, ligament, and muscle injury. For research purposes only.
- How does TB-500 compare to BPC-157?
TB-500 is studied for systemic effects and cell migration, BPC-157 for localized repair and angiogenesis. Researchers often pair them for this reason: different mechanisms, complementary targets. For research purposes only.
- How long does a TB-500 research cycle typically run?
A standard research cycle runs 4 to 6 weeks at loading dose, followed by weekly maintenance or a break. Effects in the literature build cumulatively rather than acutely. For research purposes only.